Uncontrolled type 2 diabetes mellitus (T2DM) and post‐transplant diabetes mellitus (PTDM)
increase morbidity and mortality after kidney transplantation. Conventional strategies for …

Background: This systematic review and meta-analysis aimed to evaluate the efficacy and
safety of novel antidiabetics, namely, sodium-glucose transport protein 2 inhibitors (SGLT2-i) …

Purpose of Review: Diabetes is the most common cause of kidney disease in individuals
that receive a kidney transplant, and those without pre-existing diabetes are at greater risk of …

Post-transplantation diabetes mellitus (PTDM) remains a leading complication after solid
organ transplantation. Previous international PTDM consensus meetings in 2003 and 2013 …

The management of diabetes and renal failure is changing thanks to the appearance of new
drugs such as glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose …

Background Evidence supporting glucagon-like peptide-1 receptor agonists (GLP-1RAs) in
kidney transplant recipients (KTRs) remains scarce. This systematic review and meta …

Post-transplant diabetes mellitus (PTDM) is a common occurrence in post-kidney
transplantation and is associated with greater mortality, allograft failure, and increased risk …

Introducción En los pacientes receptores de trasplante renal (TR), la diabetes mellitus (DM)
se relaciona con una mayor mortalidad y menor supervivencia del injerto. Los agonistas del …

Introduction In kidney transplant (KT) recipients diabetes mellitus (DM) are associated with
an increased mortality and a poorer graft survival. Glucagon-like peptide 1 receptor agonists …

We appreciate the interest in our work shown by the authors of this letter. 1 We fully agree
with the comment on the cardiovascular benefits of GLP-1 receptor agonists (GLP-1 RAs) as …